Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Abbvie, Celgene Corporation, Genentech, Gilead, Incyte Corporation, Jazz Pharmaceuticals, Takeda Oncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc., a subsidiary of Amgen Inc., Pharmacyclics, Sigma-Tau Pharmaceuticals, Inc., and TG Therapeutics, Inc.
19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
February 20 - 21, 2015
100 Chopin Plaza
Miami, FL 33131
Phone: (305) 577-1000
OverviewThe 19th Annual International Congress on Hematologic Malignancies® Focus on Leukemias, Lymphomas, and Myeloma provides a unique opportunity for medical oncologists, hematologists, and other healthcare professionals to interact with international leaders in the field of hematologic malignancies.
This year, we've moved the meeting to Miami, Florida and welcome two new co-chairs.
Winter Hematology® will help you stay up-to-date and give you the information that you can integrate into your practice immediately.
- Cases will focus on patient scenarios that you encounter in your practice
- Hear the experts distill the data and pinpoint what you need to know
- Presentations will hone in on the most relevant actionable information
Co-ChairsMyron S. Czuczman, MD
Professor of Oncology
Chief, Lymphoma/Myeloma Service
Department of Medicine
Head, Lymphoma Translational Research Laboratory
Department of Immunology
Roswell Park Cancer Institute
Andre Goy, MD, MS
Chairman and Director
Lymphoma Division Chief
John Theurer Cancer Center at HackensackUMC
Chief Science Officer and Director of Research and Innovation of RCCA
Professor of Medicine, Georgetown University
Target AudienceThis educational congress is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose:
Stefan Faderl, MD; Steven Horwitz, MD; Thomas Kipps, MD, PhD; Ola Landgren, MD, PhD; and Steven Treon, MD, PhD.
The staff of PER®, LLC: Ann C. Lichti, CHCP; David Lee PhD; and Megan O’Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:James Bussel, MD--Grant/ Research Support: Amgen, Cangene, GlaxoSmithKline, Genzyme, BiologicTx, Immunomedics, Ligand, Eisai, Inc, Shionogi and Sysmex; Consultant: Amgen, GlaxoSmithKline, Ligand, Shionogi, Symphogen and Eisai (Ad Boards); Stock/ Shareholder: Amgen and GlaxoSmithKline.
Myron Czuczman, MD-- Consultant: Algeta, Boehringer Ingelheim, Celgene, Gilead, Millennium, MorphoSys, Mundipharma, Teva, TG Therapeutics.
Dan Douer, MD-- Grant/ Research Support: Sigma Tai, Amgen, Bristol-Myers Squibb; Consultant: Sigma Tau and Spectrum.
Randy Gascoyne, MD-- Genentech, Roche, Celgene, Janssen and NanoString; Speaker’s Bureau-- Seattle Genetics.
Andre Goy, MD, MS-- Johnson & Johnson, Celgene (clinical trial support though institution); Consultant: Celgene; Speaker’s Bureau: Takeda; Johnson & Johnson, Pharmacyclics; Other: Advisory Board: Celgene, Takeda, Pharmacyclics, Johnson& Johnson.
Sundar Jagannath, MD-- Consultant: Celgene, Sanofi.
Jeffrey Jones, MD, MPH-- Grant Research: Genentech, Abbvie, Gilead, Pharmacyclics.
Jonathan Kaufman, MD-- Grant/ Research Support: Celgene, Merck, Novartis, Onyx; Consultant: Millennium, Celgene, Onyx, Novartis, Janssen, Spectrum.
Rami Komrokji, MD-- Grant/ Research Support: Celegene, Incyte, GlaxoSmithKline; Consultant: Celgene, Incyte; Speaker’s Bureau: Novartis.
Shuo Ma, MD, PhD-- Grant/ Research Support: NCCN, GSK, Pharmacyclics, Gilead, Abbvie, Celgene, Xeme Biopharma; Consultant: Pharmacyclics, Gilead; Speaker’s Bureau: Genentech, Janssen, Gilead.
David Maloney, MD, PhD-- Grant/ Research Support: Juno Therapeutics; Consultant: Roche/Genentech; Janssen Scientific Affairs, LLC; Seattle Genetics; Spectrum.
Michael Mauro, MD-- Grant/ Research Support: Novartis Oncology; Consultant: Novartis Oncology, Bristol-Myers Squibb, Pfizer, Ariad.
Eduardo Sotomayor, MD-- Grant/ Research Support: Acetylon Pharmaceuticals, FORMA Pharmaceuticals; Consultant: Genentech, Seattle Genetics, Gilead, Celgene.
Moshe Talpaz, MD-- Grant/ Research Support: Pfizer, Noavartis, Ariad, Sanofi, Incyte.
William Wierda, MD, PhD-- GlaxoSmithKline, AbbVie, Genentech, Karyopharm, Pharmacyclics, Ascerta, Gilead, Jansen; Consultant: Sanofi, Genentech/Roche, Pharmacyclics, Celgene, Gilead, GlaxoSmithKline, Gensyme, Merck, AbbVie, Emergent.
Thomas Witzig, MD-- Grant/ Research Support: Celgene, Novartis, Spectrum; Other: Ad Board: Amgen.
Anas Younes, MD-- Grant/ Research Support: Novartis, Johnson& Johnson, Curis; Other: Honorarium from: Bayer; Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Seattle Genetics, Takeda, Millennium.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.